|D012127||Respiratory Distress Syndrome, Newborn NIH||0.08|
|D012128||Respiratory Distress Syndrome, Adult NIH||0.07|
There is one clinical trial.
This is a prospective, randomized, single-center, open-label controlled trial, designed to compare the efficacy of two ventilation strategies (Low Tidal Volume and positive end-expiratory pressure (PEEP) based on the Acute Respiratory Distress Syndrome (ARDS) Network low PEEP-fraction of inspired oxygen inspired oxygen fraction (FIO2) Table versus Low Driving Pressure and PEEP guided by Electrical Impedance Tomography (EIT) in reducing daily lung injury score in patients with acute respiratory distress syndrome caused by COVID-19. The two strategies incorporate different prioritizations of clinical variables. The PEEP-FIO2 table strategy aims to reduce lung overdistension, even if it requires tolerating worse gas exchange. EIT-guided strategy prioritizes mechanical stress protection, avoiding alveolar overdistension and collapse.
Description: This score originally ranges from 0 to 4 points based on the average of 4 parameters (PaO2/FiO2, chest X-Ray, PEEP level, and Respiratory compliance). In the modified version, if the patient dies, he or she automatically receives a score of 5 irrespective of the other four parameters. If the patient is extubated, the score is automatically zero. We also substituted FiO2 for PEEP guaranteeing equivalence of the score when either the low or high PEEP-FiO2 table is applied.Measure: Average daily Modified Lung injury score until day 28 Time: daily
Description: Number of days with less than or equal to 1 Liter/min of oxygen supplementation until day 28Measure: High oxygen dependence free days until day 28 Time: 28 days
Description: Number of days free of mechanical ventilation assistance after protocol inclusion and before day 28Measure: Mechanical ventilation free days until day 28 Time: 28 days
Description: Occurrence of shock (persistent hypotension despite rescue measures) and incidence of barotraumaMeasure: Incidence of shock or barotrauma Time: 28 days
Description: Occurrence of acute renal failure that justifies renal replacement therapyMeasure: Incidence of acute renal failure requiring renal replacement therapy Time: 28 days
Description: Percentage of patients who died in each arm up to 28 daysMeasure: 28-day mortality Time: 28 days
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports